A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

Summary

This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC. The study will consist of several sub-studies, each evaluating the safety, tolerability, and preliminary antitumour activity of various treatment combinations. This study will be conducted in approximately 80 centers globally across 10 countries.

Timeline

Start

2025-08-07

Primary completion

2029-04-06

Completion

2029-04-06

Drugs

Indications